Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein – Research Grade

Introduction to Dalantercept Biosimilar – Anti-BMP9, BMP10 Fusion Protein

Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein is a novel therapeutic agent that has shown promising results in pre-clinical studies for the treatment of various diseases. This fusion protein is a biosimilar of Dalantercept, a human recombinant protein that acts as a potent inhibitor of the bone morphogenetic protein (BMP) signaling pathway. In this article, we will discuss the structure, activity, and potential applications of Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein.

Structure of Dalantercept Biosimilar – Anti-BMP9, BMP10 Fusion Protein

Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein is a complex protein composed of two different components – the anti-BMP9 antibody and the BMP10 fusion protein. The anti-BMP9 antibody is a monoclonal antibody that specifically binds to BMP9, a member of the BMP family of growth factors. The BMP10 fusion protein is a modified form of BMP10, which has been engineered to have a longer half-life and increased stability.

The two components of Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein are linked together by a flexible linker sequence, allowing them to function as a single unit. This fusion protein has a molecular weight of approximately 150 kDa and is produced using recombinant DNA technology in mammalian cells.

Activity of Dalantercept Biosimilar – Anti-BMP9, BMP10 Fusion Protein

Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein acts as a potent inhibitor of the BMP signaling pathway. The BMP signaling pathway is involved in various cellular processes, including cell growth, differentiation, and survival. Dysregulation of this pathway has been linked to the development and progression of many diseases, including cancer, fibrosis, and cardiovascular diseases.

The anti-BMP9 antibody component of Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein binds to BMP9 and prevents it from activating its receptors. This leads to the inhibition of downstream signaling pathways, resulting in the reduction of cell growth and survival. The BMP10 fusion protein component also plays a role in inhibiting BMP signaling by acting as a decoy receptor for BMP ligands.

Applications of Dalantercept Biosimilar – Anti-BMP9, BMP10 Fusion Protein

Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein has shown potential in the treatment of various diseases, including cancer, fibrosis, and cardiovascular diseases. In pre-clinical studies, this fusion protein has been shown to inhibit tumor growth and angiogenesis, as well as reduce fibrosis in animal models.

One of the key advantages of Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein is its ability to target two different BMP ligands – BMP9 and BMP10. This makes it a more effective inhibitor of the BMP signaling pathway compared to other single-target inhibitors. Additionally, the longer half-life of the BMP10 fusion protein component allows for sustained inhibition of BMP signaling, making it a promising therapeutic agent for chronic diseases.

Conclusion

In summary, Dalantercept Biosimilar – Anti-BMP9, BMP10 fusion protein is a novel therapeutic agent that has shown potential in the treatment of various diseases. Its unique structure and activity make it a more effective inhibitor of the BMP signaling pathway compared to other single-target inhibitors. Further studies and clinical trials are needed to fully explore the potential of this fusion protein in the treatment of different diseases.